Search results
Results from the WOW.Com Content Network
22q13 deletion syndrome, known as Phelan–McDermid syndrome (PMS), is a genetic disorder caused by deletions or rearrangements on the q terminal end (long arm) of chromosome 22. Any abnormal genetic variation in the q13 region that presents with significant manifestations ( phenotype ) typical of a terminal deletion may be diagnosed as 22q13 ...
22q13 deletion syndrome (Phelan–McDermid syndrome) [4] is a condition caused by the deletion of the tip of the q arm on chromosome 22. Most individuals with this disorder experience cognitive delays, low muscle tone, and sleeping, eating, and behavioural issues.
NNZ-2591 is a synthetic analog of cyclic glycine-proline and experimental drug developed for Angelman syndrome, Phelan-McDermid syndrome, Pitt Hopkins syndrome, [1] [2] and Prader-Willi syndrome. [ 3 ]
GeneReviews is an online database containing standardized peer-reviewed articles that describe specific heritable diseases. It was established in 1997 as GeneClinics by Roberta A Pagon ( University of Washington ) with funding from the National Institutes of Health . [ 1 ]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Phelan-McDermid_syndrome&oldid=65289780"
They often cause serious, sometimes fatal, malfunction of several different organ systems (especially the nervous system, muscles, and intestines) in affected infants. [1] The most common sub-type is PMM2-CDG (formerly known as CDG-Ia ) where the genetic defect leads to the loss of phosphomannomutase 2 ( PMM2 ), the enzyme responsible for the ...
1 in 12,000 to 20,000 people [6] Angelman syndrome ( AS ) is a genetic disorder that mainly affects the nervous system . [ 6 ] Symptoms include a small head and a specific facial appearance, severe intellectual disability , developmental disability , limited to no functional speech, balance and movement problems, seizures, and sleep problems. [ 6 ]
2-Methylbutyryl-CoA dehydrogenase deficiency is an autosomal recessive metabolic disorder. [2] It causes the body to be unable to process the amino acid isoleucine properly. Initial case reports identified individuals with developmental delay and epilepsy , however most cases identified through newborn screening have been asymptomatic .